Cardiac Troponin Assays: Analytical Issues and Clinical Reference Range Cutpoints
Overview
Toxicology
Authors
Affiliations
A recently published consensus document from the European Society of Cardiology and American College of Cardiology emphasized the unique role cardiac troponin monitoring plays in redefining acute myocardial infarction. The cardiology community has now established criteria to define both the reference cutpoints and acceptable imprecision for troponin assays, which complement previous recommendations by the laboratory community. This article will review the analytical issues confronting laboratories, clinicians, and industry regarding troponin assay standardization, assay imprecision, and how clinical decision cutpoints should be established and implemented for clinical practice.
Wang D, Zhao Y, Zhang S, Bao L, Li H, Xu J Biosensors (Basel). 2022; 12(12).
PMID: 36551074 PMC: 9775458. DOI: 10.3390/bios12121108.
Regan B, OKennedy R, Collins D Biosensors (Basel). 2018; 8(4).
PMID: 30469415 PMC: 6316850. DOI: 10.3390/bios8040114.
Frenkel D, Pachori A, Zhang L, Dembinsky-Vaknin A, Farfara D, Petrovic-Stojkovic S Int Immunol. 2009; 21(7):817-29.
PMID: 19515797 PMC: 2699489. DOI: 10.1093/intimm/dxp051.
The reporting of cardiac troponin.
Hickman P, Koerbin G, Tate J Clin Biochem Rev. 2008; 24(4):99-108.
PMID: 18568050 PMC: 1853350.